SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435445.
  • 2
    McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of the patients responded to a four-dose treatment program. J Clin Oncol 1998;16:28252833.
  • 3
    Perrota A, Sunneberg TA, Scott J, Ratanatharaphorn V, Hook C, Attas L, Dawson D, Kunkel LA. Rituxan in the treatment of chronic idiopathic thrombocytopenia purpura (ITP). Blood 1999;94(Suppl 1):14.
  • 4
    Mow BM, Hook CC. Rituximab for the treatment of refractory immune thrombocytopenic purpura—case report. Blood 1999;94(Suppl 1):82b.
  • 5
    Ratnatharathorn V, Carson E, Reynolds C, Ayesh LJ, Yanik G, Silver SM, Ferrara JL, Ubereti JP. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Int Med 2000:133:4:275279.